We demonstrated that DTIC/Epacasome-2 elicited markedly higher tumour-infiltrating levels of NKG2D (receptor)+/NK+ cells, CD69+/NK+ cells, IFN-γ+/NK+ cells, Perforin+/NK+ cells, and Granzyme B+/NK+ cells, as well as NKG2D (receptor)+/CD8+ T cells, CD69+/CD8+ T cells, IFN-γ+/CD8+ T cells, Perforin+/CD8+ T cells and Granzyme B+/CD8+ T cells, in comparison to the co-administration of DTIC/Lipo-SM/Chol and Epacasome-2 or monotherapy alone. The gene discussed is CD69; the disease is neoplasm.